LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Elenco Azioni・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

41.02 -0.12

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

41.02

Massimo

41.02

Metriche Chiave
By Trading Economics
Entrata	100M 19M
Vendite	68M 268M
P/E Media del settore	38.337 51.415
EPS	0.15
Margine di Profitto	6.954
Dipendenti	733
EBITDA	74M 27M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-3.51% downside

Dividendi
By Dow Jones
Utili prossimi	30 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	6.4M 5.3B
Apertura precedente	41.14
Chiusura precedente	41.02

Notizie sul Sentiment di mercato

By Acuity

83%

17%

325 / 346 Classifica in Healthcare

Apellis Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mag 2026, 22:27 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mag 2026, 22:12 UTC

Utili

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mag 2026, 21:52 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs

15 mag 2026, 00:00 UTC

Utili

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mag 2026, 23:57 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mag 2026, 23:56 UTC

Discorsi di Mercato

Gold Prices Rise on Strong Demand -- Market Talk

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mag 2026, 23:47 UTC

Utili

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mag 2026, 23:47 UTC

Utili

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mag 2026, 23:28 UTC

Discorsi di Mercato

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 mag 2026, 22:35 UTC

Discorsi di Mercato

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mag 2026, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mag 2026, 22:06 UTC

Discorsi di Mercato

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mag 2026, 22:04 UTC

Utili

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mag 2026, 22:00 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q EPS 18c >NU

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q Rev $4.97B >NU

Confronto tra pari

Modifica del prezzo

Apellis Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

-3.51% in calo

Previsioni per 12 mesi

Media 39.59 USD -3.51%

Alto 41 USD

Basso 28 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Apellis Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Apellis Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

325 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.